Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02468661
Title A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib

Capmatinib + Erlotinib

Erlotinib

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL


No variant requirements are available.